Benzinga · Oct 29, 2026
Canaccord Genuity Maintains Buy on Biogen, Raises Price Target to $272
Canaccord Genuity analyst Sumant Kulkarni maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $248 to $272.
NASDAQ · BIIB
Biogen Inc.
Healthcare · Drug Manufacturers - General
$253.62
Up+$3.97 (+1.59%)
Updated Nov 2, 2026, 10:01 AM
SID Score
7.1/10
Composite research score
Smart Money
52/100
Neutral
- Market cap
- 25.33B
- P/E ratio
- 15.74
- Dividend yield
- 0.00%
- 52-week range
- $160.36 – $258.78
- Volume
- 1.3M
- Avg. volume
- 1.8M
Price performance · BIIB
BIIB price history
1M range · 0 trading sessions · Daily adjusted prices
BIIB does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest BIIB news
The latest Smart Investors Daily articles mentioning BIIB.
Stock researchCompany · Overview
Company
Market Activity
Research & News
BIIB research
Overview
Company profile and research snapshot.
Company profile
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $177.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 29, 2026 | Argus Research | Buy | — |
| Oct 29, 2026 | Canaccord Genuity | Buy | — |
| Oct 29, 2026 | TD Cowen | Buy | — |
| Oct 29, 2026 | UBS | Buy | — |
| Oct 29, 2026 | Morgan Stanley | Equal-Weight | — |
News briefing
No generated briefing is available yet.
Benzinga · Oct 29, 2026
Argus Research Upgrades Biogen to Buy, Announces $280 Price Target
Argus Research analyst Jasper Hellweg upgrades Biogen (NASDAQ:BIIB) from Hold to Buy and announces $280 price target.
Yahoo · Oct 29, 2026
Biogen Swings Back to Growth as Stock Momentum Could Continue, RBC Says
Biogen (BIIB) has swung back to growth as shown by its solid Q3 results, RBC analysts wrote in a not
Benzinga · Oct 29, 2026
RBC Capital Maintains Outperform on Biogen, Raises Price Target to $272
RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $256 to $272.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
